Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R.

J Immunol. 2019 May 15;202(10):2888-2906. doi: 10.4049/jimmunol.1800583. Epub 2019 Apr 15.

2.

Semiquantitative Nucleic Acid Test with Simultaneous Isotachophoretic Extraction and Amplification.

Bender AT, Borysiak MD, Levenson AM, Lillis L, Boyle DS, Posner JD.

Anal Chem. 2018 Jun 19;90(12):7221-7229. doi: 10.1021/acs.analchem.8b00185. Epub 2018 May 25.

3.

Effective Rheology of Two-Phase Flow in Three-Dimensional Porous Media: Experiment and Simulation.

Sinha S, Bender AT, Danczyk M, Keepseagle K, Prather CA, Bray JM, Thrane LW, Seymour JD, Codd SL, Hansen A.

Transp Porous Media. 2017;119(1):77-94. doi: 10.1007/s11242-017-0874-4. Epub 2017 Jun 13.

4.

Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.

Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, Head J, Morandi F, Haselmayer P, Liu-Bujalski L.

Mol Pharmacol. 2017 Mar;91(3):208-219. doi: 10.1124/mol.116.107037. Epub 2017 Jan 6.

PMID:
28062735
5.

Btk inhibition treats TLR7/IFN driven murine lupus.

Bender AT, Pereira A, Fu K, Samy E, Wu Y, Liu-Bujalski L, Caldwell R, Chen YY, Tian H, Morandi F, Head J, Koehler U, Genest M, Okitsu SL, Xu D, Grenningloh R.

Clin Immunol. 2016 Mar;164:65-77. doi: 10.1016/j.clim.2016.01.012. Epub 2016 Jan 25.

6.

In Situ Detection of Subsurface Biofilm Using Low-Field NMR: A Field Study.

Kirkland CM, Herrling MP, Hiebert R, Bender AT, Grunewald E, Walsh DO, Codd SL.

Environ Sci Technol. 2015 Sep 15;49(18):11045-52. doi: 10.1021/acs.est.5b02690. Epub 2015 Sep 3.

PMID:
26308099
7.

Assessment of the translational value of mouse lupus models using clinically relevant biomarkers.

Bender AT, Wu Y, Cao Q, Ding Y, Oestreicher J, Genest M, Akare S, Ishizaka ST, Mackey MF.

Transl Res. 2014 Jun;163(6):515-32. doi: 10.1016/j.trsl.2014.01.003. Epub 2014 Jan 6.

PMID:
24462761
8.

Indeterminate leprosy and lepromatous index case: four cases in the same family.

Silva VP, Fonseca HH, Sens MM, Bender AT.

An Bras Dermatol. 2013 Nov-Dec;88(6 Suppl 1):105-8. doi: 10.1590/abd1806-4841.20132050.

9.

Evaluation of a candidate anti-arthritic drug using the mouse collagen antibody induced arthritis model and clinically relevant biomarkers.

Bender AT, Spyvee M, Satoh T, Gershman B, Teceno T, Burgess L, Kumar V, Wu Y, Yang H, Ding Y, Akare S, Chen Q.

Am J Transl Res. 2013;5(1):92-102. Epub 2013 Jan 21.

10.

Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages.

Hertz AL, Bender AT, Smith KC, Gilchrist M, Amieux PS, Aderem A, Beavo JA.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21978-83. doi: 10.1073/pnas.0911684106. Epub 2009 Dec 3.

11.

Treatment with the specific estrogen receptor antagonist ICI 182,780 demasculinizes neuron soma size in the developing zebra finch brain.

Bender AT, Veney SL.

Brain Res. 2008 Dec 30;1246:47-53. doi: 10.1016/j.brainres.2008.09.089. Epub 2008 Oct 14.

PMID:
18952068
12.
13.

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Bender AT, Beavo JA.

Pharmacol Rev. 2006 Sep;58(3):488-520. Review.

PMID:
16968949
14.
15.

Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation.

Bender AT, Ostenson CL, Wang EH, Beavo JA.

Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):497-502. Epub 2004 Dec 29.

16.

Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages.

Bender AT, Beavo JA.

Neurochem Int. 2004 Nov;45(6):853-7. Review.

PMID:
15312979
18.

Assembly and activation of heme-deficient neuronal NO synthase with various porphyrins.

Bender AT, Kamada Y, Kleaveland PA, Osawa Y.

J Inorg Biochem. 2002 Sep 20;91(4):625-34.

PMID:
12237228
19.

Alteration of the heme prosthetic group of neuronal nitric-oxide synthase during inactivation by N(G)-amino-L-arginine in vitro and in vivo.

Vuletich JL, Lowe ER, Jianmongkol S, Kamada Y, Kent UM, Bender AT, Demady DR, Hollenberg PF, Osawa Y.

Mol Pharmacol. 2002 Jul;62(1):110-8.

PMID:
12065761
20.

hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase: geldanamycin-mediated oxidant generation is unrelated to any action of hsp90.

Billecke SS, Bender AT, Kanelakis KC, Murphy PJ, Lowe ER, Kamada Y, Pratt WB, Osawa Y.

J Biol Chem. 2002 Jun 7;277(23):20504-9. Epub 2002 Mar 28.

21.

Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme.

Demady DR, Jianmongkol S, Vuletich JL, Bender AT, Osawa Y.

Mol Pharmacol. 2001 Jan;59(1):24-9.

PMID:
11125020
22.

Heme insertion, assembly, and activation of apo-neuronal nitric-oxide synthase in vitro.

Bender AT, Nakatsuka M, Osawa Y.

J Biol Chem. 2000 Aug 25;275(34):26018-23.

23.

Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase.

Jianmongkol S, Vuletich JL, Bender AT, Demady DR, Osawa Y.

J Biol Chem. 2000 May 5;275(18):13370-6.

24.

Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo.

Bender AT, Demady DR, Osawa Y.

J Biol Chem. 2000 Jun 9;275(23):17407-11.

25.

Guanabenz-mediated inactivation and enhanced proteolytic degradation of neuronal nitric-oxide synthase.

Noguchi S, Jianmongkol S, Bender AT, Kamada Y, Demady DR, Osawa Y.

J Biol Chem. 2000 Jan 28;275(4):2376-80.

26.

Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo.

Bender AT, Silverstein AM, Demady DR, Kanelakis KC, Noguchi S, Pratt WB, Osawa Y.

J Biol Chem. 1999 Jan 15;274(3):1472-8.

Supplemental Content

Loading ...
Support Center